key: cord-0276988-6kx9ovwz
authors: Wang, Peng; Ye, Yihong
title: Filamentous recombinant human Tau activates primary astrocytes via an integrin receptor complex
date: 2020-11-14
journal: bioRxiv
DOI: 10.1101/2020.05.07.083295
sha: 49ed18f50ba71dc620fb4dbda5f1036ee4c62731
doc_id: 276988
cord_uid: 6kx9ovwz

Microtubule-associated protein Tau can form protein aggregates transmissible within the brain, correlating with the progression of tauopathies in humans. The transmission of aggregates requires neuron-released Tau to interact with surface receptors on target cells. However, the underlying molecular mechanisms in astrocytes and downstream effects are unclear. Here, using a spatially resolved proteomic mapping strategy, we show that integrin αV/β1 receptor binds recombinant human Tau, mediating the entry of Tau fibrils in astrocytes. The binding of distinct Tau species to the astrocytic αV/β1 receptor differentially activate integrin signaling. Furthermore, Tau-mediated activation of integrin signaling results in NFκB activation, causing upregulation of pro-inflammatory cytokines and chemokines, induction of a sub-group of neurotoxic astrocytic markers, and release of neurotoxic factors. Our findings suggest that filamentous recombinant human Tau-mediated activation of integrin signaling induces astrocyte conversion towards a neurotoxic state, providing a mechanistic insight into tauopathies.

Clinically documented protein aggregates such as extracellular amyloid plaques and intracellular neurofibrillary tangles (NFTs) are pathological hallmarks of neurodegenerative diseases such as Alzheimer's disease (AD). NFTs are formed primarily by hyperphosphorylated Tau, a soluble microtubule-binding protein abundantly expressed in neurons of the central nervous system (CNS) 1, 2 . The primary function of Tau is to stabilize microtubules, but its intrinsic misfolding propensity prompts it to form toxic filamentous aggregates, particularly in neurons during aging. In addition to AD, Tau-containing NFTs have been linked to brain dysfunctions in other neurodegenerative diseases such as Pick's disease and frontotemporal dementia, which are collectively termed Tauopathies 1 .

An unusual characteristic of tauopathies is the prion-like propagation of Taucontaining aggregates, which seems to correlate with the decline of cognition during disease progression [1] [2] [3] [4] [5] [6] . This protein propagation process may involve the release of Tau in either monomeric or aggregated forms, followed by the uptake by recipient cells (neurons or glial cells) 7 . Tau fibrils formed along this path can serve as 'seeds' once inside a target cell, converting endogenous Tau monomers into an aggregation-prone toxic conformer. Accumulating evidence suggests that both monomeric Tau and Tau aggregates can be released from neurons independent of cell death, and this process is enhanced by neuronal activities [8] [9] [10] . The mechanisms underlying Tau release are controversial.

Specifically, some studies showed that Tau is predominantly released in a free soluble form [11] [12] [13] [14] but a study suggested membrane-associated vesicles as a major extracellular Tau carrier 8 . By contrast, numerous studies showed that neurons, microglia, and 4 astrocytes all could readily internalize different Tau species [15] [16] [17] [18] . In certain immortalized cells, endocytosis of Tau preformed fibrils (PFFs) is initiated when Tau binds to heparan sulfate proteoglycans (HSPGs) on the cell surface [19] [20] [21] , which cooperate with a membrane receptor to mediate Tau internalization 22 , but other unidentified mechanisms also contribute to Tau uptake, particularly in primary non-neuronal cells 22, 23 .

In addition to damaging endogenous Tau folding when Tau PFFs enter neurons, Tau fibrils can also influence non-neuronal cells from the cell exterior. This model is particularly attractive in the complex brain microenvironment in which the fitness of neurons is tightly modulated by glial cells such as astrocytes 24, 25 . It was shown that the activation of astrocytes by lipopolysaccharide (LPS) can alter their phagocytic activity, which might mitigate Tauopathies as activated astrocytes help to clear protein aggregates 26, 27 . However, activated astrocytes might also exacerbate Tauopathies because they can contribute to neuroinflammation by releasing pro-inflammatory cytokines and chemokines 28, 29 . Notably, a recent transcription profiling study revealed two distinct functional states of reactive astrocytes termed as "A1" and "A2", respectively 30 . A2 astrocytes appear to restore neuronal activities after injury, whereas A1 astrocytes not only fail to promote synapse formation, but also gain a neurotoxic activity by releasing some unknown factors.

How astrocytes are converted to a neurotoxic state is a key question relevant to many neurodegenerative diseases. To date, accumulating evidence suggest that microglia activated during the classic inflammation response can serve as an essential mediator of astrocytic A1 conversion because factors released by reactive microglia are sufficient to 5 activate the astrocyte A1 state 30 . However, whether neurotoxic astrocytes can be induced independent of microglia under stress or disease conditions is unknown.

Given the close link between Tau misfolding and neurodegenerative diseases, we ] investigate whether harmful insults triggered by extracellular Tau aggregates can directly convert astrocytes to a neurotoxic state. We used a proximity-based ligation approach to identify the αV/β1 integrin complex as a receptor for Tau monomer and fibrils in primary astrocytes. The ligation of Tau fibrils to integrin not only initiates their internalization, but also activates integrin signaling, which in turn induces inflammation and converts astrocytes into an A1-like neurotoxic state. These findings establish a direct link between misfolding-associated proteotoxic stress and astrocyte activation.

To study the mechanism of Tau fibril uptake in primary astrocytes, we purified Tau (2N4R) as a recombinant protein from E. coli ( Supplementary Fig. 1a ) and labeled it with a fluorescent dye (Alexa594). We used the labeled protein to generate PFFs following a wellestablished protocol ( Supplementary Fig. 1b) 31 , and then treated mouse primary astrocytes with labeled monomeric Tau or PFFs. Incubating astrocytes with Tau for up to 6 h did not cause detectable cell death ( Supplementary Fig. 1c ) but led to efficient internalization of Tau PFFs. Unlike immortalized cell lines, Tau PFF uptake by primary astrocytes was largely unaffected by heparin ( Supplementary Fig. 1d, e) , a competitive inhibitor that blocks Tau PFF binding to HSPGs in some cell lines [19] [20] [21] . This result is in line 6 with another study, which suggests that primary astrocytes do not use HSPGs for Tau PFF internalization 32 . Instead, an unknown Tau receptor(s) is involved.

Because Tau monomers could also enter primary astrocytes, albeit with reduced efficiency compared to Tau PFFs 15, 32 , we presumed that Tau fibrils and monomers engaged a common receptor but with different affinities. Therefore, we employed a proximity labelingbased proteomic mapping strategy using purified APEX2-tagged Tau monomer as the bait ( Figure 1a ). APEX2 is an engineered peroxidase that can covalently tag proximal lysine side chains with biotin molecules in the presence of biotin-phenoxyl radicals 33 . Because the relatively large APEX2 fusion might affect the interaction of Tau with the plasma membrane, we first used Sh-SY5Y cells to characterize the membrane interaction of Tau fusion proteins (Figure 1b) . When APEX2 was fused to the C-terminus of Tau, Tau-APEX2 bound efficiently to the cell surface in a dose dependent manner, but the addition of APEX2 to the N-terminus abolished the binding ( Supplementary Fig. 2a, b) . Thus, consistent with previous reports 34, 35 , Tau binding to the plasma membrane is mediated by a sequence near the N-terminus, which can be masked by a proximal APEX2 fusion.

To identify Tau receptor, we incubated Tau-APEX2 or APEX2 as a control with primary astrocytes at 4 °C for 30 min to allow membrane binding. This short incubation did not affect membrane permeability or induce cell death ( Supplementary Fig. 2c) . We then performed biotin labeling and the labelled plasma membrane proteins were enriched 7 by streptavidin-affinity purification. Immunoblotting using biotin antibodies detected a major biotinylation product with Mr. of ~120kDa ( Figure 1c ). As expected, APEX2 alone was not able to biotinylate this 120kDa protein (Figure 1c) . Mass spectrometry analysis of the excised band identified several membrane proteins enriched in Tau-APEX2-treated cells ( Supplementary Fig. 2d) . Interestingly, the top candidates were all cell adhesion molecules such as integrins and neural cell adhesion molecules (NCAM).

The identification of integrin as a potential Tau receptor was intriguing given that genetic variations in integrin genes had been suggested as a potential risk factor for neuroinflammation/neurodegeneration [36] [37] [38] and that α6/β1 integrin was shown to facilitate phagocytosis-mediated elimination of Aβ amyloid 39, 40 . Since αV/β1 integrin (ITGαV/β1) was the most significantly modified proteins (based on peptide count), we focused this study on ITGαV/β1.

To validate the interaction of Tau-APEX2 with αV/β1 integrin, we repeated Tau-APEX2-mediated biotinylation using HEK293T cells over-expressing either Flag-tagged ITGαV or GFP-tagged ITGβ1. Following cell surface biotinylation and streptavidin pulldown, these proteins could be detected by immunoblotting using antibodies recognizing their corresponding tags (Figure 1d, Supplementary Fig. 2e ), suggesting that they could indeed be biotinylated by Tau-APEX2. Similar experiments performed in primary astrocytes further confirmed that endogenous ITGαV/β1 could be biotinylated by Tau-APEX2 but not APEX2 (Figure 1e ). Importantly, after Tau-APEX2 binding to the cell surface, immunoprecipitation of Tau-APEX2 from cell extracts using a Tau specific 8 antibody also co-precipitated endogenous ITGαV/β1 ( Figure 1f ). Likewise, when Tau-APEX2 was incubated with purified ITGαV/β1 ectodomains, immunoprecipitation of Tau also co-precipitated ITGαV/β1 ( Supplementary Fig. 3a) . Thus, the biotinylation of ITGαV/β1 by Tau-APEX2 is likely a result of a direct interaction between these proteins.

We next tested whether Tau PFFs also interacted with endogenous ITGαV/β1 by coimmunoprecipitation. To this end, we incubated primary astrocytes in the presence or absence of Tau PFFs on ice before solubilizing cells by a NP40-containing buffer.

Immunoprecipitation using Tau antibodies precipitated Tau PFFs together with a fraction of endogenous ITGαV/β1 (Figure 2A , lane 9). By contrast, ITGαV/β1 was not precipitated when Tau PFF was omitted or when a control antibody was used (lanes 7, 8). We conclude that ITGαV/β1 also interacts with Tau PFFs and thus may serve as a receptor for both monomeric and filamentous Tau.

We next tested whether ITGαV/β1 mediates Tau PFF cell entry. We generated lentiviruses expressing small hairpin RNAs (shRNAs) that specifically knocked down ItgαV or Itgβ1 (Figure 2b , c). Knockdown of ItgαV and Itgβ1 either individually or in combination did not affect the viability of astrocytes, but significantly reduced Tau PFF internalization ( Supplementary Fig. 3b, Figure 2d , e, f). Furthermore, knockdown of Talin1, an adaptor essential for integrin signaling and integrin-mediated endocytosis 41-43 also led to a significant reduction in Tau PFF uptake (Figure 2e , f, g). The fact that knockdown of three different integrin pathway components all reduced Tau PFF uptake ruled out the possibility of an off-target effect. Intriguingly, treating cells with a potent inhibitor (PF-562271) of the focal adhesion kinase (FAK), an essential integrin regulatory kinase downstream of Talin1 did not affect Tau PFF endocytosis (Figure 2h , i), nor did it affect cell viability ( Supplementary Fig. 3c ). These results suggest that binding to ITGαV/β1 triggers Tau PFF cell entry, which requires Talin1 but not the downstream integrin signaling.

The ligation of ligands such as fibronectin to integrin activates integrin signaling, changing the expression of many downstream genes 44 . To test whether Tau also activated integrin signaling, we treated primary astrocytes with monomeric Tau, Tau PFFs, or as a control with phosphate buffer saline (PBS) for 6 h. qRT-PCR analyses of a collection of integrin target genes (Mmp9, Icam1, Mmp13 etc.) 45, 46 showed that compared to PBS-treated cells, Tau monomer and PFFs differentially activated the expression of many integrin target genes with Tau PFF being ~2-3fold more potent than monomeric Tau ( Figure 3a ). As anticipated, PFF-induced integrin activation could be mitigated if astrocytes were first infected with lentiviruses that knocked down ItgαV and Itgβ1 (Figure 3b ).

Because astrocytes purified by the conventional method also contain some microglia and oligodendrocytes, we used immunopanning-purified astrocytes to further validate Tau PFF-induced integrin signaling (Figure 3c ) (see the methods).

Immunostaining using an antibody against the astrocyte-specific marker GFAP showed that purified astrocytes were free of other cell types. Immunopurified astrocytes internalized Tau PFFs similarly as conventionally purified astrocytes (Figure 3c ). These cells also activated integrin target genes after being stimulated by Tau PFFs (Figure 3d ), which was reproducibly diminished when Talin1 was depleted ( Figure 3d ). Altogether, these data suggest that like canonical integrin ligands, the interactions of Tau and Tau PFFs with ITGαV/β1 also activate integrin signaling.

As a major immune-competent cell in the CNS, astrocytes can sense danger signals and elicit an immune response via the secretion of pro-or anti-inflammation cytokines and chemokines 28, 47 . We analyzed the mRNA expression of a collection of cytokine and chemokine genes by qRT-PCR in astrocytes exposed to Tau monomer or Tau PFFs using PBS-treated cells as a reference. Intriguingly, PFF treatment caused a strong induction of several pro-inflammatory cytokines (IL1α，IL1β，IL6, TNFα) and chemokines (Ccl2, Ccl3, Ccl4, Cxcl10). By contrast, the expression of Clc12 and several anti-inflammation cytokines/chemokines such as IL10 and TGFβ was not affected (Figure 4a, 

Tau also activated pro-inflammatory cytokines/chemokines, but consistently to lower levels ( Figure 4a , b), suggesting that integrin activation by Tau might be coupled to inflammation induction. Indeed, the induction of pro-inflammatory genes by Tau PFFs was largely abolished in integrin αV/β1 knockdown astrocytes ( Figure 4c ). Thus, ITGαV/β1 is required for a Tau PFF-induced pro-inflammation response in astrocytes. 11 Astrocyte activation is usually linked to increased expression of the NO synthase (NOS2) 48 , which upregulates the production of nitric oxide (NO) during inflammation 49 .

Indeed, qRT-PCR detected a significant increase in the expression of NOS2 in astrocytes following Tau PFF treatment. Like integrin target genes, NOS2 expression was also induced by monomeric Tau, albeit by a smaller magnitude (Figure 4d ), and the depletion of ItgαV/β1 significantly reduced Tau PFF-induced NOS2 expression (Figure 4e ).

To further elucidate the functional link between Tau PFF-induced integrin signaling and astrocytic inflammation, we used immunopurified astrocytes to test the requirement of Talin1 and FAK in PFF-induced inflammation. As expected, Tau PFF treatment induced the expression of pro-inflammation cytokines and chemokines such as IL1α, IL1β, IL6, TNFα, Ccl2, Ccl3, Ccl4, Cxcl10 as well as the IL1 downstream gene NOS2, but noticeably, the induction of IL1α, IL1β and NOS2 by Tau PFF was much higher than that seen in conventionally purified astrocytes ( To test the role of FAK in Tau PFF-induced inflammation, we pre-treated immunopurified astrocytes with the FAK inhibitor PF-562271, which dose-dependently abolished Tau PFF-induced expression of pro-inflammatory genes ( Supplementary Fig.   4a , Figure 4j , k). Thus, Tau PFF-induced inflammation requires Talin1 and FAK.

Because NFkB is a central regulator of inflammation and because integrin activation has been linked to NFkB signaling 50, 51 , we used qRT-PCR to measure the expression of NFkB in PFF-and monomeric Tau-treated astrocytes. For comparison, we also tested STAT3, another inflammation regulatory transcription factor 52 . Indeed, NFkB but not STAT3 was activated by Tau PFFs and also to a lesser extent by monomeric Tau (Figure 5a ). 

A recent study suggested that extracellular factors in the brain microenvironment can 13 cause native astrocytes to adopt different functional states 30 . These states are linked to the expression of pan-reactive genes and certain A1-or A2-specific genes. Since Tau PFFs activate integrin signaling and induce inflammation, we tested whether PFF-treated astrocytes resemble the neurotoxic A1 state or the neuroprotective A2 state by determining the expression of the previously characterized pan-reactive, A1 and A2 signature genes. Interestingly, qRT-PCR showed that both Tau monomer and PFFs induced the expression of many pan-reactive and A1 specific genes such as Gbp2, H2-T23, Ggta, Ligp1, Psmb8 etc with PFFs generally causing a higher level of induction than monomer ( Figure 6a ). By contrast, most A2 genes were not significantly affected with the exception of Cd14, Tgm1, and Ptx3. Thus, monomeric Tau and Tau PFF appear to convert astrocytes into an A1-like state. Knockdown of either ItgαV/β1 or Talin1 dramatically reduced Tau PFF-associated gene induction (Figure 6b, c, Fig. S5 ), so did the treatment with PF-562271 and the NF kB inhibitor PDTC (Pyrrolidine dithiocarbamate) 50 (Figure 6d , e) . Thus, Tau PFFs alter astrocytes in an integrin-dependent manner, converting them to an A1-like state.

To further test whether Tau PFFs converted astrocytes into a neurotoxic state, we treated astrocytes with PBS, monomeric Tau, or Tau PFFs for 6 h and then replated these cells in a Tau-free medium for 48 h. After incubation, many cells treated by Tau PFFs displayed a tadpole-like morphology, which was not seen in monomeric Tau or PBS-treated samples 14 ( Supplementary Fig. 6a ). We then used the conditioned medium (CM) from these cells to treat mouse cortical neurons. No Tau carryover was detected in CM ( Supplementary Fig.   6b ). However, when neuronal cell death was monitored 72 h later by a fluorescence-based cell viability assay (Figure 7a ), the CM from Tau PFF-treated cells was significantly more toxic than that from PBS-or monomeric Tau-treated astrocytes. Interestingly, the CM from PFF-treated, ITGαV/β1 knockdown astrocytes had a significantly reduced neurotoxic activity compared to the CM from PFF-treated control cells (Figure 7b , c). These results suggest that Tau PFF-treated astrocytes release a neurotoxic factor(s) in an ITGαV/β1dependent manner.

The accumulation and propagation of Tau filamentous aggregates are observed in a broad spectrum of neurodegenerative disorders including AD 1, 53 . The progressive spreading of Tau inclusions, which has been recapitulated in mouse models 4, 5, 54 , is thought to take place along neuronal connections or via unconventional protein secretion followed by cell uptake 7, 55 . Tau-containing aggregates have also been detected in glial cells (both microglia and astrocytes), although endogenous Tau is not expressed in these cells. This suggests that pathological Tau inclusions may also be transmitted from neurons to glia [56] [57] [58] [59] . Importantly, expression of human Tau in glia in a Drosophila model led to neurotoxicity, suggesting that Tau, if propagated into glial cells, might have a pathogenic activity 60 .

Likewise, in a transgenic mouse model, astrocytic expression of human Tau using the astrocyte-specific GFAP (glial fibrillary acidic protein) promoter leads to neurodegeneration 61 . These results demonstrate that the prion-like transmission of Tau aggregates from neurons to glia may contribute to neurodegeneration. However, it is unclear whether it is the internalized Tau fibrils or an interplay between the extracellular Tau and a cell surface receptor(s) that causes neurotoxicity.

In this study, we show that Tau filamentous aggregates bind to an integrin receptor complex (ITGαV/β1) on the astrocyte surface, which not only mediates Tau fibril uptake, but also regulates fibril-induced inflammation and astrocytic conversion (Figure 7d ).

ITGαV/β1, as a member of the integrin family, is a cell surface adhesion molecule that binds to extracellular matrix proteins 44 . This activates integrin signaling, which has been linked to cancer cell invasion and proliferation 44, 46 ; Through the actin-binding protein 2) Microglia can take up fibrillar AD-associated β-Amyloid (Aβ) aggregates via ITGα6/β1

and an integrin-associated protein CD47 39 ; 3) The expression of β1 integrin is elevated in cortical astrocytes from AD patients, and in AD-related animal models β1 integrin can mediate soluble Aβ oligomers-induced astrogliosis 64 ; 4) A more recent study revealed that in response to spinal cord injury, which is often associated with the release of stressinducing factors such as misfolded proteins, astrocytes are activated via an integrin and cadherin-dependent mechanism to form astrocytic scars 65 . In light of these observations and our findings, we propose that integrin receptors on astrocytes may sense extracellular Astrocytes, as the most abundant glial cells in the CNS, are a well-established modulator of neurodegeneration-associated inflammation 47 . Specifically, diseaseassociated abnormal proteins such as Aβ and α-Syn fibrils can change astrocyte physiology. For instance, different Aβ species can activate disparate astrocytic cell receptors to induce the pro-inflammatory NF-κB pathway [68] [69] [70] [71] . Our study shows that extracellular Tau aggregates can impact astrocytes similarly, suggesting a unified interplay between extracellular misfolded proteins and astrocytes.

Importantly, our study shows that Tau PFF-activated astrocytes resemble the neurotoxic A1 state reported recently 30 . This gain-of-function state, which has been associated with astrocytic inflammation, was suggested to play a causal role in neurodegeneration, but the upstream signals that promote astrocytic activation are unclear. Particularly, existing evidence suggests that the A1 state could only be achieved by a relayed signal elicited from microglial cells exposed to an extracellular insult such as LPS. By contrast, we showed that even in the absence of microglia, misfolded Tau aggregates can trigger astrocyte activation via ITGαV/β1. This suggests that astrocytic inflammation may be a key contributor to tauopathies. Additionally, given that neurons are usually the major source of secreted Tau, our findings raise the possibility that astrocytes may monitor the healthy state of neurons by sensing the level of misfolded Tau released.

It is conceivable that Tauopathies in neurons at low levels may be mitigated by intercellular transmission and astrocyte-mediated clearance, but at high levels will activate astrocytes, which release neurotoxic factors to cause neurodegeneration. This model opens a venue for drug development aimed at preventing astrocytic activation in tauopathies.

Wild-type C57BL/6J mice were purchased from the Jackson Laboratories. All animals were maintained in accordance with the animal care standards of the National Institutes of Health. All reagents are listed in Supplementary table 1.

Primary astrocyte cultures were prepared from cerebral cortices of P2-P5 C57BL/6J mice. Single-cell suspension of the digested tissue was obtained by repeated pipetting. Cells were seeded into a 75 ml flask at a density of ~4 × 10 5 cells/cm 2 and cultured in astrocyte culture medium at 37 °C in a humidified 5% CO2 incubator. Monolayers of glial cells were obtained 7-10 days after plating. To remove microglia, cultures were gently shaken, and the floating cells (microglia) were removed, resulting in more than 95% pure astrocytes.

The remaining astrocytes were incubated for 72 h before being infected with lentivirus or other experiments. Before experiments, astrocytes were dissociated by trypsinization and then reseeded at 4 × 10 5 cells cm 2 or 1.5 × 10 5 cells per well in 24-well or 1.5 × 10 6 cells per well in 6-well or 2 × 10 5 cells cm 2 in Labtek imaging dish in DMEM F12 50/50 containing 10% FBS and 1% penicillin-streptomycin. At the start of each experiment, the medium was 19 changed to regular DMEM without serum and antibiotics.

Astrocytes were purified by immune-panning from P2-P5 C57BL/6J mice and cultured as previously described 72 . Briefly, cortices were digested by Trypsin at 37 °C and then mechanically dissociated to generate single-cell suspension, which was incubated in successive negative immune-panning plates to remove macrophage and microglia cells before positive selection for astrocytes by an ITGβ5-coated panning plate. Isolated astrocytes were cultured in a defined, serum-free base medium containing 50% neurobasal, 50% DMEM, 100 U/ml penicillin, 100 μg/ml streptomycin, 1 mM sodium pyruvate, 292 μg/ml L-glutamine, 1 x G5 supplement. This medium was supplemented with the astrocyte-required survival factor HBEGF (Peprotech, 100-47) at 5 ng/ml as previously described 73 .

Primary neuron cultures were either purchased from Thermo Fisher Scientific or prepared from cerebral cortices of P0-P1 C57BL/6 mice. Cortices were dissected, stripped of meninges, and digested with 0.25% trypsin at 37 °C in HBSS for 10 min. Trypsinization was stopped by the addition of FBS. A single-cell suspension of the digested tissue was obtained by repeated pipetting. Cells were seeded into a 24 well plate at a density of 1.5

x 10 5 cells per well and cultured in DMEM culture medium supplemented with 10% fetal bovine serum (Thermo Fisher), 100 U/ml of penicillin, 0.1 mg/ml of streptomycin (Thermo Fisher), 25 mM glucose, 4 mM glutamine, and 1 mM sodium pyruvate at 37 °C. At 24 h 20 after seeding, the medium was changed with Neurobasal medium (Thermo Fisher) supplemented with B-27 (Thermo Fisher) containing 0.5 mM glutamine. Cells were cultured at 37 °C in a humidified chamber supplemented with 5% CO2. Cultures were used for experiments from 7 to 10 days after seeding.

The recombinant human (Tau 2N4R isoform), containing 2 N-terminal inserts and 4 microtubule binding repeats was isolated as previously described 31 

The condition for Tau polymerization is: 50 μM purified Tau protein, 12.5 μM heparin, a protease inhibitor cocktail (10 μg/ml leupeptin, 5 μg/ml chymostatin, 3 μg/ml elastatinal, and 1 μg/ml pepstatin), and 2 mM DTT in phosphate buffer saline (PBS). This solution was incubated at 37 °C for two weeks. Tau polymerization is induced by the addition of heparin. 

5 mg/ml Tau filaments were diluted 10-fold in PBS and loaded onto an EM grid. The grid was then washed with pure water and stained with 3% uranyl acetate for 1 min and then imaged with a Morgagni 268 transmission electron microscope. 22 Tau fibrils were diluted in PBS and sonicated with 10 pulses of 30 % amplitude before being added to culture medium. Primary astrocyte culture was treated with 200 nM Tau filament-Alexa Fluor 594 for 2 hours in the astrocyte culture medium. In the case of inhibitor treatment, culture was pretreated with 10 μM PF262271 for 2 hours. Cells were either directly imaged using a Zeiss LSM780 confocal microscope or fixed with 4% paraformaldehyde in PBS before imaging.

RNA isolation was performed using a RNeasy Mini Kit (Qiagen) according to the manufacturer's protocol. RNA concentration was measured using Nanodrop-1000. 

For Lentivirus production, two 15 cm dishes of HEK293FT cells were seeded at 40% 23 confluence. On the next day, 1 h prior to transfection, the medium was replaced with 13 ml pre-warmed Opti-MEM medium (Thermo Fisher). Transfection was performed using 

Immunoblotting was performed using a standard protocol. Proteins were separated in NuPAGE (4%-12%) Bis-Tris gels (Thermo Fisher) and transferred onto nitrocellulose membranes (Bio-Rad). The target protein was detected by specific primary antibodies followed by secondary horseradish peroxidase (HRP)-conjugated antibodies (for less abundant proteins) (Sigma) or fluorescence-labeled secondary antibodies (for abundant antigens) (Thermo Fisher). For immunoblotting with HRP-conjugated secondary antibodies, the signal was detected by the enhanced chemiluminescence method (ECL) using the Immobilon western chemiluminescent HRP substrate (Millipore) and recorded by a Fuji LAS-4000 image reader. The intensity of the detected protein bands was quantified by ImageGauge v3.0 software. For immunoblotting with fluorescence-labeled secondary antibodies, membranes were scanned using a LI-COR Odyssey scanner. The intensity of the protein bands was quantified by the LI-COR Odyssey v3.1 software.

Cells were washed with pre-cold PBS two times to remove serum completely. We prepared 200 nM Tau-Apex2 or Apex2 proteins in serum-free pre-cold F-12 medium (5 ml for each 15 cm petri dish). We incubated cells with these proteins for 30 minutes at 4℃ with gentle shaking. After incubation, we removed the unbounded proteins by thoroughly washing the cells 3 times, each with 6 ml pre-cold F12 medium. We then incubated cells in 500 µM Biotin-phenol (BP) in F-12 serum-free medium (10 ml for one 15 cm petri-dish)

pre-warmed to 37 ℃. After 30 minutes of incubation, we added freshly prepared H2O2 stock solution (100 mM) into the cells to achieve a final concentration of 1 mM. Cells were incubated further at room temperature for 4 min. The medium was removed and cells were washed twice with the quencher solution (10 mM sodium ascorbate, 5 mM Trolox, and 10 mM sodium azide in DPBS.), followed by two washes with DPBS, and then resuspended in the quencher solution. Collect Cells were pelleted by centrifugation at 3,000 g for 10 min at 4℃, lysed in 7 ml PBS-based lysis buffer with 0.5% NP40, a protease inhibitor cocktail, 1 mM DTT, 10 mM sodium azide, 10 mM sodium ascorbate and 5 mM Trolox).

After incubation on ice for 40 min, cell extracts were cleared by centrifugation at 15,000 g for 10 min at 4 ℃. Cleared supernatant was incubated with 50 µl pre-washed streptavidin beads, gently rocked at 4 ℃ for 1 h. The beads were extensively washed with PBS containing 0.05% NP40. Bound proteins were eluted in 50 µl 1x sample buffer. Proteins 26 were fractionated on a SDS-PAGE gel. Proteins in excised bands were identified by the Taplin Mass Spectrometry core at Harvard Medical School as fee for service.

Astrocytes were infected with shRNA-expressing lentivirus on 72 h after plating. Cells were grown for a total of 7 days in serum-free medium supplemented with 5 ng/ml 

All data generated for this study are included in this article and its supplementary materials. Source data is available from the corresponding author upon reasonable request. Dots represent the average fluorescence intensity/cell from images (>20 cells/image) acquired.

(g) As in b, except that Talin1 mRNA expression was determined after Talin1 knockdown. 35 Mean± SEM, n=4 biologically independent samples. The numbers and asterisks above indicate p value (****, p<0.0001) determined by twotailed unpaired t-test. (h, i) Tau PFF-induced inflammation is suppressed by a NFkB inhibitor. As in d, except that cells were pre-treated with PDTC (90 μM) for 1 h before Tau PFF and PBS treatment and that the indicated genes were analyzed. Mean ±SEM, n=3 independent experiments.

The numbers and asterisks above indicate p value (****, p<0.0001) determined by twotailed unpaired t-test. (a) A heat map shows the expression of pan-reactive, A1 and A2 signature genes in Tau monomer-and PFF-treated primary astrocytes (200 nM, 6h), which is normalized to PBStreated cells. Shown is the average of 3 independent experiments. Asterisks indicate p value (*, p<0.05; **, p<0.01; ***, p<0.001) from two-tailed unpaired t-test. 39 (b) The expression of the indicated A1 genes were analyzed by qRT-PCR from PBS-or Tau PFF-treated (200 nM, 6h) astrocytes, which had been infected with lentiviruses (72 h) expressing control or ITGαV/β1 shRNAs. Fold changes (FC) were normalized to PBStreated samples. Mean ±SEM, n=3 independent experiments each with 2 technical duplicates.

(c) As in b, except that immunopurified astrocytes infected with control-or Talin1 (TLN1) shRNA-expressing lentiviruses were used. Mean ±SEM, n=4 biologically independent samples. 

Neurodegenerative tauopathies

Tau pathology and neurodegeneration

Prion-like mechanisms in neurodegenerative diseases

Transmission and spreading of tauopathy in transgenic mouse brain

Templated misfolding of Tau by prion-like seeding along neuronal connections impairs neuronal network function and associated behavioral outcomes in Tau transgenic mice

What is the evidence that tau pathology spreads through prion-like propagation?

Regulation of protein homeostasis by unconventional protein secretion in mammalian cells

Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease

Physiological release of endogenous tau is stimulated by neuronal activity

Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons

Constitutive secretion of tau protein by an unconventional mechanism

Paired helical filaments from Alzheimer disease brain induce intracellular accumulation of Tau protein in aggresomes

DnaJ/Hsc70 chaperone complexes control the extracellular release of neurodegenerative-associated proteins

DNAJC5 facilitates USP19-dependent unconventional secretion of misfolded cytosolic proteins

TFEB enhances astroglial uptake of extracellular tau species and reduces tau spreading

Propagation of tau misfolding from the outside to the inside of a cell

Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy

Extracellular Monomeric and Aggregated Tau Efficiently Enter Human Neurons through Overlapping but Distinct Pathways

Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds

Specific glycosaminoglycan chain length and sulfation patterns are required for cell uptake of tau versus alpha-synuclein and beta-amyloid aggregates

Tau Internalization is Regulated by 6-O Sulfation on Heparan Sulfate Proteoglycans (HSPGs)

LRP1 is a master regulator of tau uptake and spread

Normal and Pathological Tau Uptake Mediated by M1/M3 Muscarinic Receptors Promotes Opposite Neuronal Changes

Glia as architects of central nervous system formation and function

Role of astrocytes, microglia, and tanycytes in brain control of systemic metabolism

Adult mouse astrocytes degrade amyloid-beta in vitro and in situ

Enhancing astrocytic lysosome biogenesis facilitates Abeta clearance and attenuates amyloid plaque pathogenesis

Astrocyte barriers to neurotoxic inflammation

How neuroinflammation contributes to neurodegeneration

Neurotoxic reactive astrocytes are induced by activated microglia

Purification of recombinant tau protein and preparation of Alzheimer-paired helical filaments in vitro

Extracellular Monomeric Tau Is Internalized by Astrocytes

Spatially resolved proteomic mapping in living cells with the engineered peroxidase APEX2

Interaction of tau with the neural plasma membrane mediated by tau's amino-terminal projection domain

Dynamic association of tau with neuronal membranes is regulated by phosphorylation

Functional screening in Drosophila identifies Alzheimer's disease susceptibility genes and implicates Tau-mediated mechanisms

Single-cell mass cytometry reveals distinct populations of brain myeloid cells in mouse neuroinflammation and neurodegeneration models

Integrin Beta 3 Regulates Cellular Senescence by Activating the TGFbeta Pathway

Microglial phagocytosis of fibrillar beta-amyloid through a beta1 integrin-dependent mechanism

The alpha5beta1 integrin mediates elimination of amyloid-beta peptide and protects against apoptosis

Talin binding to integrin beta tails: a final common step in integrin activation

Integrin activation by talin, kindlin and mechanical forces

Talin -the master of integrin adhesions

Structural and signaling functions of integrins

Neuron-released oligomeric alpha-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia

Every step of the way: integrins in cancer progression and metastasis

Astrocytes: Key Regulators of Neuroinflammation

Expression of nitric oxide synthase-2 (NOS-2) in reactive astrocytes of the human glaucomatous optic nerve head

Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity

Alpha 5 beta 1 integrin activates an NF-kappa B-dependent program of gene expression important for angiogenesis and inflammation

NF-kappaB in the nervous system

STATs in cancer inflammation and immunity: a leading role for STAT3

Neuropathological stageing of Alzheimer-related changes

Propagation of tau pathology in a model of early Alzheimer's disease

Tau pathology spread in PS19 tau transgenic mice following locus coeruleus (LC) injections of synthetic tau fibrils is determined by the LC's afferent and efferent connections

Glial Tau Pathology in Tauopathies: Functional Consequences

Direct Evidence of Internalization of Tau by Microglia In Vitro and In Vivo

Tau accumulation in astrocytes in progressive supranuclear palsy is a degenerative rather than a reactive process

Thorn-shaped astrocytes: possibly secondarily induced tau-positive glial fibrillary tangles

Glial fibrillary tangles and JAK/STAT-mediated glial and neuronal cell death in a Drosophila model of glial tauopathy

Transgenic mouse model of tau pathology in astrocytes leading to nervous system degeneration

Extracellular matrix molecules and their receptors: functions in neural development

Integrins in the development, function and dysfunction of the nervous system

Amyloid beta-induced astrogliosis is mediated by beta1-integrin via NADPH oxidase 2 in Alzheimer's disease

Interaction of reactive astrocytes with type I collagen induces astrocytic scar formation through the integrin-N-cadherin pathway after spinal cord injury

Regulation of Transmembrane Signaling by Phase Separation

The final steps of integrin activation: the end game

Involvement of Astrocytes in Alzheimer's Disease from a Neuroinflammatory and Oxidative Stress Perspective

Astrocyte s RAGE: More Than Just a Question of Mood

Astrocytes are important mediators of Abeta-induced neurotoxicity and tau phosphorylation in primary culture

Beta-amyloid stimulation of inducible nitric-oxide synthase in astrocytes is interleukin-1beta-and tumor necrosis factor-alpha (TNFalpha)-dependent, and involves a TNFalpha receptor-associated factor-and NFkappaB-inducing kinasedependent signaling mechanism

Purification of rat and mouse astrocytes by immunopanning

Development of a method for the purification and culture of rodent astrocytes

Scale bar, 10 μm. (c) Quantification of dead cells labeled by ethidium homodimer-1 in randomly selected fields. Mean± SEM, n=3 biologically independent samples. The numbers and asterisks above indicate p value

A working model showing the interplays between Tau-PFF, astrocytes and neurons

We thank R. Tycko (NIDDK) for assistance with the negative stain EM, J. Reece (NIDDK) for imaging assistance, Q. Zhang and Y. Xu (NIDDK) for critical reading of the manuscript. P. Wang, and Y. Ye are supported by an intramural research program of NIDDK.

P. Wang, and Y. Ye designed the research, analyzed the data. P. Wang performed the experiments. P. Wang and Y. Ye wrote the paper together.

The authors declare no competing financial interest.